zanamivir


Also found in: Medical, Wikipedia.
Related to zanamivir: amantadine, Oseltamivir, Relenza

za·na·mi·vir

 (zə-nä′mə-vîr′)
n.
An antiviral drug, C12H20N4O7, that is used in inhalant form for the treatment and prevention of influenza.

zanamivir

(zəˈnæməˌvɪə)
n
a drug used to treat influenza
Translations

zanamivir

n zanamivir m
Mentioned in ?
References in periodicals archive ?
The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing services of Influenza Medication Market products such as Zanamivir, Oseltamivir, Peramivir, and others as well as new entrants planning to enter this market.
Because the patient's respiratory symptoms worsened and influenza B persisted despite treatment, we replaced oseltamivir with intravenous zanamivir (600 mg 2x/d) but switched back to oseltamivir because of respiratory distress episodes.
GSK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for intravenous zanamivir for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when the patients influenza virus is known or suspected to be resistant to anti-influenza agents other than zanamivir, and/or other anti-viral agents for treatment of influenza, including inhaled zanamivir (Relenza), are not suitable for the individual patient.
He said Oseltamivir and Zanamivir were anti vital drugs, which were used for treatment and prevention of the infection.
The present study evaluated the anti-influenza efficacy of the potent neuraminidase inhibitor zanamivir and ion channel blockers amantadine in avian species using chickens.
Oseltamivir and zanamivir are competitive inhibitors for the neuraminidase enzyme for the influenza virus.
Other NA inhibitors approved by the FDA for influenza infection include oseltamivir, which is orally administered, and zanamivir, which is inhaled.
" Constantly evolving viral genome induces resistance against current anti- influenza drug regimens comprising newly developed drugs such Tamiflu, zanamivir, amantadine, etc.
At present influenza A(H1N1)pdm09, A(H3N2) and B viruses remain sensitive to oseltamivir and zanamivir. A small proportion of A(H1N1) pdm09 viruses with highly reduced inhibition (HRI) by oseltamivir have been detected globally.
In the study, published April 10 in the Cochrane Database of Systematic Reviews, investigators analyzed data from 20 trials involving oseltamivir (Tamiflu[R]) and 26 trials involving zanamivir (Relenza[R]), encompassing a total of more than 24,000 people.
The two most commonly used antiviral drugs for treating influenza infections, oseltamivir and zanamivir, each provide a net benefit to patients compared with no treatment, concluded the authors of a meta-analysis of 74 influenza antiviral observational studies.